Infleqtion, Inc. (NYSE: INFQ) — Quantum’s Cheapest Pure-Play, Buried Under Its Own de-SPAC Supply

Independent Equity Research Report date: 2026-07-30 · Coverage: Initiation Price (2026-07-30): ~$9.98 · Shares out: 218.2M (10-Q cover, 2026-05-12) · Market cap: ~$2.18B Cash + AFS securities (3/31/26): ~$568.7M · Total debt: none · Implied EV: ~$1.61B FY2025 revenue: $32.5M · FY2025 GAAP operating loss: −$35.3M · 2026 revenue guidance: “at least $40M” Sector: Information Technology · Quantum Computing

The analysis in Sections 1–15 below carries no investment recommendation and no price target. It presents evidence — with fact and interpretation explicitly labeled where it matters — together with scenario analysis, not advice. The single exception is the Claude's Take block immediately following, which is the author’s own subjective opinion.

⚡ Claude’s Take

The author’s own subjective opinion. General information only — not investment advice. The analytical body (Sections 1–15) below carries no position and no price target.

Verdict: Speculative HOLD / watchlist — the cheapest ticket in the quantum cohort with the most real revenue, but a falling knife with ~6 weeks of visible supply overhang and a Q2 print on 2026-08-12. Do not chase it, do not short it. Directional scenario zone (values, not targets): bear ~$3.7 / base ~$8 / bull ~$16.

The contrarian case is real and it is arithmetic, not narrative. At ~$9.98, INFQ trades at ~48x trailing EV/Sales against a listed quantum pure-play cohort priced at 148x (IONQ), 640–900x (RGTI), ~650x (QBTS) and ~950x (QUBT) — an order-of-magnitude discount — while carrying the cohort’s second-largest revenue base ($33.7M TTM vs IONQ’s $130M; everyone else is at $12M or below), positive growth, a raised guide, and ~$568.7M of liquidity with no debt (CFO, Q1-2026 call, 2026-05-14: “$569 million… with no debt”). Roughly 26% of the share price is net cash (~$2.6/share), the clean operating burn is ~$8.5–9M a quarter against that pile, and ~85% of revenue is government money that is genuinely contracted. If you must own a quantum pure-play, this is the only one where the market is paying a mid-double-digit multiple for revenue that mostly exists.

The knife case is equally real, and it is why the discount exists. This is a government-funded R&D contractor wearing a quantum-computing multiple: one customer was 61% of Q1 revenue, remaining performance obligations are only ~$19.5M against a $40M guide, gross margin halved to 21% y/y, DARPA’s QBI Stage B — the USG’s own handicap on who reaches utility-scale — excluded Infleqtion while both neutral-atom rivals advanced, and the float has been detonated by the de-SPAC machinery: the $12 VWAP early-release trigger freed the lockup by ~April, five 424B3 resale registrations have landed in 14 weeks, Maverick Capital dumped 16.78M shares (~$262M) in May with its own managing partner on the board, two other VCs distributed ~50M shares in-kind, the CEO exercise-and-sold ~$13M, and not one insider has bought a share on the way from $18 to $9. The tape confirms it: lower highs since the 6/2 peak close of $19.87, price below every EMA, −53% off the April high, ~13% short float and rising. The framing fight is contrarian de-SPAC-supply vs falling knife — and the momentum read says the knife has not stopped falling: today’s +13% bounce came on below-average volume off a near-all-time-low, a reflex rally, not a base. Note also what the scenario work implies: even the ~$8 base case sits below the current price — the tape already discounts successful execution of the guide. The ~$16 bull case requires the $100M Commerce LOI to convert and the 100-logical-qubit roadmap to hold; the ~$3.7 bear case only requires quantum-winter sentiment and award slippage. Not a short: 26% cash backing, the cohort’s relative cheapness, a beta of ~4.4, and a stock that can squeeze +31% on a single Washington headline make the short side structurally dangerous.

Tag: “The only quantum stock priced like a contractor — because that is what it is.”

Conviction: medium. What flips me bullish: conversion of the ~$100M Commerce CHIPS LOI into a definitive funded contract (an 8-K event) — it would validate the sovereign-demand thesis with dollars, not letters. What flips me bearish: a cut to the “at least $40M” guide at the 2026-08-12 Q2 print in a year that is already H2-weighted against a ~$19.5M backlog.

📈 Stock Price Action — Listing-to-Date Event Map

INFQ has only ~5 months of public history: the Churchill Capital Corp X business combination closed 2026-02-13 and INFQ began trading on the NYSE on 2026-02-17 (debut close $15.59); vendor price rows before that date are the CCCX SPAC mapped onto the ticker (8-K, 2026-02-03, Item 3.01). The arc in one sentence: a post-announcement SPAC premium bled to trust value into the vote, popped on the debut, set its all-time intraday high of $21.28 within nine weeks on analyst initiations and a sector-wide government-funding day, and has since been ground down −53% by an unrelenting sequence of resale registrations and insider/VC supply, back below the $10.00 PIPE price. The moves below are FACT (AZI price series, 141 trading days); the attributed drivers are INTERPRETATION.

Cycle narrative. (1) The September 2025 announcement put a story-stock premium on the CCCX shell that bled back to trust value as the February vote approached — classic redemption-arb mechanics. (2) The debut pop to $15.59 lasted five weeks before the resale S-1 and 10-K (both 2026-03-31) made the coming float concrete; the stock broke $10 and printed its all-time low of $8.52 the day before. (3) April brought the fundamental catalysts — FY2025 results, the ~$40M guide, and two buy-side initiations leaning on the NVIDIA narrative — and the stock nearly doubled off the low to its $21.28 intraday high. (4) May delivered the single best and single most revealing day: Q1 results with a raised guide were sold (−19% over three sessions) into simultaneous resale registrations, then the Commerce LOI headline lifted the whole sector +12–33% with INFQ +31.5% on 6x average volume. (5) Everything since the 2026-06-02 peak close of $19.87 has been one trade: supply. Lower highs ($19.87 → $17.4 → $14.6 → $12.3 → $9.98), five 424B3s in 14 weeks, VC distributions and insider sales absorbed by a retail-heavy tape turning over ~5% of market cap daily. The stock closed ≥$12 essentially every session from listing through mid-July — which is precisely what triggered the lockup’s early release and kept the registry machine running. Today’s +13% bounce on below-average volume is the first uptick of consequence in seven weeks; the first stabilization evidence, on a trend-following read, would be a reclaim and hold of the 21-EMA (~$10.5) on rising volume — which has not happened.

1. Executive Summary

Infleqtion, Inc. — formerly ColdQuanta, Inc., a Boulder, Colorado neutral-atom quantum technology company spun out of JILA/CU-Boulder — became public on 2026-02-17 as the de-SPAC successor to Churchill Capital Corp X (Michael Klein franchise), in an all-stock deal struck at a $1.8B equity value with a $126.5M PIPE at $10.00 and near-zero redemptions (8-K, 2026-02-17). It is the only listed neutral-atom pure-play: a company built on laser-cooled atoms that sells five product lines — Sqale quantum computers, Tiqker optical atomic clocks, SqyWire (“Quantum Spectrum”) RF sensors, eXaqt inertial/gravity sensors, and software (the Superstaq compiler and CML quantum-inspired AI) — into a customer base that is ~85% government (Q1-2026 10-Q, filed 2026-05-15).

The bull facts are the best in the listed cohort. FY2025 revenue was $32.5M — up from $28.8M in FY2024 and $10.9M in FY2023 — “100% organic and entirely from quantum” (CEO Kinsella, FY2025 call, 2026-04-08); Q1-2026 revenue was a record $9.5M, +14% y/y, and management raised 2026 guidance from “approximately $40 million” to “at least $40 million… we deliberately changed to at least $40 million” (Q1-2026 call, 2026-05-14). Only IONQ ($130M FY2025) has more revenue among listed pure-plays; RGTI’s is $7.1M and falling, QUBT’s is $682K. The balance sheet is a fortress: ~$568.7M of cash and available-for-sale securities at 3/31/26 against no debt, raised at de-SPAC with 0.09% redemptions — a best-case outcome. At ~$9.98 the market cap is ~$2.18B, the ex-cash EV ~$1.61B, and the trailing EV/Sales multiple ~48x — cheap by exactly one comparison (the quantum cohort, at 148x–950x) and expensive by every other.

The bear facts are structural. Revenue is ~85% government, milestone-based, terminable for convenience, and concentrated: one customer was 61% of Q1-2026 revenue. Contracted backlog is thin — remaining performance obligations of ~$19.5M at 3/31/26 against a $40M guide — so the year leans on new awards. Gross margin halved y/y to 21.0% in Q1 on mix shift toward lower-margin service/development contracts. On the metric that matters for the compute thesis, logical qubits, Infleqtion’s 12 trails private rivals QuEra (96, Nature-published), Quantinuum (48) and Atom Computing (24) — and DARPA’s Quantum Benchmarking Initiative advanced both neutral-atom rivals to Stage B in November 2025 while excluding Infleqtion. The de-SPAC machinery has been hostile to the tape: the $12-VWAP early-release trigger freed the lockup by ~April 2026, ~121.8M shares were registered for resale within two months of listing, five 424B3s have followed, and the insider record since is 100% sell / 0% buy — Maverick Capital’s 16.78M-share, ~$262M liquidation (a board member’s fund), ~50M shares of VC in-kind distributions, and ~$18M of executive sales including the CEO’s ~$13M.

Capital allocation, capital-cycle, and valuation all resolve to the same tension. The deal itself was shareholder-friendly by de-SPAC standards (flat $10 PIPE, small earn-out already triggered, equity-classified warrants), and the $568.7M hoard funds the roadmap for years without a raise. But the sector sits in the late stage of a Marathon capital cycle — ~$6.3B raised across 47 deals in the trailing year, Quantinuum’s ~$1.7B June IPO, serial issuance everywhere — and Infleqtion’s own share count is already creeping (+0.8% in one quarter) under a heavy equity-comp culture. Scenario work frames the embedded expectations honestly: a bear case near ~$3.7 (awards stall, multiple compresses to ~10x sales), a base case near ~$8 (guide met, 25–30% CAGR, ~15x forward sales) — below today’s price — and a bull case near ~$16 (Commerce LOI converts, compute scales to ~$150M+ revenue by 2029). This memo takes no position; the framework below argues the evidence.

Verdict: See Claude's Take above for the single subjective view. The institutional summary: the strongest revenue-and-balance-sheet fundamentals in the listed quantum cohort, wrapped in the weakest technical-validation and supply-dynamic story in the cohort — and priced, rationally or not, at the intersection of the two.

2. Business Overview

What the company is. Infleqtion is a neutral-atom quantum technology company headquartered in Boulder, Colorado (~55% of staff in the Denver metro), with 205 employees of whom more than 160 are physicists and engineers (10-K, filed 2026-03-31). The corporate lineage matters: the operating company is ColdQuanta, Inc., founded on JILA/CU-Boulder cold-atom science (co-founder Dana Anderson), renamed Infleqtion pre-deal, and brought public via reverse recapitalization into Churchill Capital Corp X with ColdQuanta as the accounting acquirer — so the financial history below is the operating company’s, audited by KPMG since 2022, not the SPAC shell’s. Management is new-public-company vintage: Matthew Kinsella (ex-Maverick Ventures MD, first investor and board member since 2018, CEO since April 2024), CTO Pranav Gokhale (via the 2022 Super.tech acquisition), CFO Ilan Hart, CRO Paul Lipman (closing 8-K, 2026-02-17).

What it sells — one physics core, five product lines. Every product is built on the same neutral-atom/cold-atom platform (10-K Item 1; S-4):

• Sqale quantum computers. On-premises systems plus cloud QCaaS sold in “shots.” The flagship technical claims: a 1,600-trapped-atom array (“industry’s largest neutral atom array outside of a research institution,” Dec 2025), 12 logical qubits demonstrated (2025, against 8 targeted), 99.73% two-qubit CZ gate fidelity, room-temperature operation with reconfigurable all-to-all connectivity. The roadmap, repeated verbatim on both post-listing calls: 2 logical qubits (2024) → 12 (2025) → 30 (targeted 2026) → 100 (targeted 2028), with CTO Gokhale framing 100 logical qubits as “the point at which quantum begins to unlock transformative applications… first… in material science around the end of the decade” (Q1-2026 call, 2026-05-14).
• Tiqker optical atomic clocks. The most commercial product: compact, rack-mountable precision timing for PNT (positioning/navigation/timing). The 10-Q states commercial product revenue is “primarily from selling Tiqker for PNT use cases”; proof points are an ~$11M APFIT award to field rack-mounted units and a Safran Electronics & Defense co-launched Tiqker-based timing product (announced with FY2025 results, April 2026).
• SqyWire / “Quantum Spectrum” quantum RF sensors. Demonstrated at Army NetModX23 with L3Harris under a classified DoW program; management’s #2 sensing revenue contributor and “being accelerated” (Q1-2026 call).
• eXaqt inertial/gravity sensors. The navigation and gravimetry line; its anchor is the NASA Quantum Gravity Gradiometer (QGG) Pathfinder, where Infleqtion is prime sensor developer/integrator under $20M of contracts to date (including a $17M September 2025 modification). Cold Atom Lab hardware arrived at the ISS in April 2026.
• Software. Superstaq, a hardware-agnostic compiler/middleware (2022 Super.tech acquisition), and CML — “contextual machine learning,” quantum-inspired AI running on classical NVIDIA GPUs, explicitly not quantum computing. DARPA selected Infleqtion for the HARC program’s software track — the only hardware company on it (CTO, Q1-2026 call).

How it actually makes money. The single reportable segment produced FY2025 revenue of $32.46M (product $19.6M / service $12.9M) and Q1-2026 revenue of $9.46M (product $3.15M, −51% y/y; service $6.31M, +232%, mostly +$4.0M from the NASA QGG contract). Two facts define the model. First, the customer base: government customers were 85% of Q1-2026 revenue (84% a year earlier); the U.S. government (prime or sub) was ~60% of FY2025 revenue, the UK government ~12%, Australia ~6%; named customers and partners run through DoW, DARPA, NASA, DOE, the service branches, UK NQCC, Japan’s Moonshot program (Infleqtion is its only foreign QC partner, per the S-4), Lockheed Martin, SAIC, L3Harris, NVIDIA and Safran. Second, the contract shape: 91% of Q1-2026 revenue was recognized over time — milestone/percent-complete government R&D contracts — versus 9% point-in-time product. This is cost-plus-adjacent revenue: real, auditable, and low-visibility.

What it does not (yet) make money on. QCaaS/cloud compute revenue is immaterial — the 10-K itself calls it “a very early stage of commercialization”; Superstaq licenses exist but were ~$0.6M of the FY2024 narrative; CML’s revenue evidence is two ~$1–2M Army/Navy SBIR-scale awards (SAPIENT, QuIRC). Management’s own mix framing is “~2/3 sensing / ~1/3 computing” with “wide error bars” (Kinsella, Q1-2026 call).

Backlog and visibility. Remaining performance obligations at 3/31/26 were ~$19.5M — $17.2M due in 2026, $2.2M in 2027, $0.1M thereafter (10-Q). Against the “at least $40M” guide, roughly half the year’s revenue is not yet under contract. Compare IONQ’s $470M RPO. The de-SPAC-era marketing metric — “~$50M booked and awarded business by YE2025” (Rule 425 materials, Sept/Nov 2025) — was never restated post-listing, and no backlog/bookings figure is disclosed on either earnings call: a disappearing metric worth remembering when management cites its “$300M+ pipeline” (surfaced once, via an analyst question about the 2026-03-11 Analyst Day).

Verdict: FACT — Infleqtion is a government-funded R&D organization with a genuinely emerging product line attached, closer in economic substance to a small defense-tech contractor than to a scaling hardware or software company. INTERPRETATION — the bull’s “diversified quantum platform” framing is half-true: the sensing lines (Tiqker, SqyWire, eXaqt) generate the near-term revenue and are genuinely differentiated; the computing line (Sqale) is presently a science project with a ticker that consumes most of the R&D. The filings are notably more sober than the press releases.

3. Industry Dynamics

The listed quantum industry is pre-commercial, subsidized, and profit-pool negative. Across the pure-play cohort (IONQ, RGTI, QBTS, QUBT, now INFQ), total commercial revenue is a few hundred million dollars globally, not one company earns an operating profit, and the group collectively burns well over $1B a year against tens of billions of market capitalization (per those companies’ own FY2025 SEC filings). The industry is funded by capital markets and governments, not customers.

The modality war is genuinely unsettled — and neutral atoms have moved up. The map: superconducting (IBM, Google, Rigetti — fast gates, cryogenic overhead, fault-tolerance roadmaps ~2029); trapped ion (IONQ, Quantinuum — highest fidelities, 99.99%/99.92%, slow gates); photonic (PsiQuantum, $1.3B+ raised; Xanadu SPAC at $3.6B); annealing (D-Wave — special-purpose, non-universal); and neutral atom (Infleqtion, Atom Computing, Pasqal, QuEra — identical-by-nature qubits, room-temperature operation, dynamically reconfigurable large arrays, no cryogenics). FACT: neutral atoms have moved from dark horse to credible top-3 modality on demonstrated progress — QuEra published 96 verified logical qubits (Nature, January 2026) and Atom Computing demonstrated 24 with Microsoft (Nov 2024). INTERPRETATION: this validates Infleqtion’s modality choice — but the modality’s demonstrated leaders are private, leaving Infleqtion as the public-market proxy for neutral atoms rather than their technical leader. Part of INFQ’s float demand is simple scarcity: it is the only listed neutral-atom name.

The USG handicap that matters: DARPA QBI. The Quantum Benchmarking Initiative is the closest thing to an official U.S. government assessment of who can reach utility-scale quantum computing by 2033. In November 2025 DARPA advanced 11 companies to Stage B — IBM, IonQ, Quantinuum, Atom Computing, QuEra and others. Both of Infleqtion’s direct neutral-atom rivals are in; Infleqtion is not (Nextgov, 2025-11-07). Infleqtion was instead selected for DARPA’s HARC program — the software track, where it is the only hardware company. A new QBI Stage-A solicitation has abstracts due 2026-07-31 — tomorrow, and a live watch item.

TAM honesty. Infleqtion’s own 10-K cites third-party forecasts of ~$130B for quantum computing by 2040 and ~$30B for quantum sensing by 2040 — fourteen-year-out projections in the BCG/McKinsey “$1T by 2040” genre that deserve to be treated as fantasy-grade. Current actual industry revenue is roughly two orders of magnitude below any near-term TAM figure. The demand that exists today is government: the ~$1.2B National Quantum Initiative reauthorization, the $250M QBI appropriation, export controls, sovereign-quantum procurement (the UK’s up-to-£2B announcement citing Infleqtion’s NQCC delivery, Japan, Australia, Illinois’ $50M park), and the May 2026 Commerce CHIPS R&D/NIST letters of intent — $2.013B across nine quantum companies including equity stakes, with Infleqtion allocated $100M of planned funding (NIST, 2026-05-21). Government demand is a genuine cycle floor for revenue — and it produces cost-plus economics, not profit pools.

Marathon capital-cycle read: textbook late stage. Capital supply is exploding — ~$6.3B across 47 deals in the trailing ~12 months (New Market Pitch, 2026-07-17); Quantinuum raised $600M at a $10B pre-money (Nov 2025) then a ~$1.7B IPO (June 2026); Xanadu de-SPAC’d at $3.6B; QUBT raised $1.5B of equity in 2025; IONQ sits on $3.1B; D-Wave issued >$1B in nine quarters; QuEra took $230M including NVIDIA’s NVentures; Infleqtion itself raised ~$528M gross via de-SPAC. Asset growth via issuance, deeply negative returns on capital industry-wide, sovereign funds and corporate VCs sprinkling across rivals — the framework predicts poor cohort-level equity returns as multiples mean-revert toward the (negative) fundamentals; timing is unknowable, but this is the phase of the cycle where capital is cheapest and discipline is lowest.

Structural verdict (Greenwald lens applied to the industry). An industry with no settled winner, no switching costs (cloud backends are a recompile away), no scale economies yet in evidence, government-shaped demand, and competition from hyperscalers with effectively unlimited R&D budgets is not an industry where equity returns are underwritten by structure — they are underwritten by picking the winner early, at a price that already assumes you did.

Verdict: structurally bad industry for equity returns at prevailing cohort valuations — with one exception that matters for INFQ. Quantum sensing (PNT timing, RF, gravity) is a nearer-term, genuinely procurable market where demand exists today — smaller, defense-procurement-shaped, and contested (Microchip, Safran/Orolia, Vector Atomic-now-inside-IonQ), but real. Infleqtion’s revenue realism is the direct product of serving the unglamorous half of the industry.

4. Competitive Position

The claimed advantages, as filed (10-K/S-4): (a) the 1,600-atom array, largest outside a research institution; (b) 12 logical qubits demonstrated, 100 targeted by 2028; © 99.73% two-qubit CZ fidelity; (d) room-temperature, cryogenics-free architecture with reconfigurable connectivity; (e) program incumbency — NASA QGG prime ($20M), ~$11M APFIT Tiqker fielding, UK NQCC Sqale delivery (the UK’s largest quantum computer, its only operational 100+ physical-qubit system), Japan Moonshot partnership, DARPA HARC; (f) JILA/CU-Boulder IP heritage — exclusive CU and WARF licenses (subject to Bayh-Dole march-in and government-use rights), a patent portfolio the 10-K calls the deepest in cold-atom systems, >160 scientists and engineers; (g) the NVIDIA ecosystem relationship (CUDA-Q logical-qubit materials demo, Dec 2024; NVQLink system to Illinois, Oct 2025; Sqale QPU at the GTC booth, Mar 2026).

Pressure test #1 — the NVIDIA “partnership” confers no moat. FACT: it is a technology collaboration, not an investment or exclusivity — and NVIDIA’s venture arm invested in QuEra, Infleqtion’s direct neutral-atom rival (September 2025). NVIDIA hedges across every modality; CUDA-Q works with everyone. INTERPRETATION: the NVIDIA logo is distribution plumbing and marketing, not a barrier.

Pressure test #2 — on the metric that matters, Infleqtion is mid-pack. Logical qubits are the field’s accepted currency. Infleqtion’s 12 trails QuEra (96, Nature-published), Quantinuum (48) and Atom Computing (24). Its 99.73% CZ fidelity trails IonQ (99.99%) and Quantinuum (99.92%), though it leads Rigetti (99.1%). The 1,600-atom array lead is a physical-qubit-count claim — the easiest metric to inflate and the least tied to error-corrected performance. Management’s own KPI answer is instructive: asked by JPMorgan which metrics to watch, Kinsella named exactly two — revenue versus guidance, and logical qubits (FY2025 call, 2026-04-08).

Pressure test #3 — the DARPA exclusion. FACT: Infleqtion is not among the 11 companies advanced to QBI Stage B; both neutral-atom rivals are. INTERPRETATION: the USG’s own utility-scale handicap currently does not include Infleqtion’s computing roadmap. This is the single most damaging competitive fact in the file, and bears will cite it in every note. Mitigants: HARC software-track selection is a genuine middleware credibility signal, and the new Stage-A solicitation (abstracts due 2026-07-31) is a re-entry path.

Pressure test #4 — what actually ties to a financial outcome. The sensing franchise is the only claim with visible financial substance: Tiqker generates commercial product revenue today, has a fielding-scale DoD award (APFIT ~$11M), a tier-1 defense-electronics go-to-market partner (Safran), and a space-grade path (NASA QGG prime). Everything in the computing column is R&D-contract revenue and milestone promises.

Greenwald taxonomy, applied honestly: no durable competitive advantage. Demand side: no switching costs (cloud backends are a recompile away; sensing customers re-compete; government contracts are terminable for convenience), no network effects, no customer captivity beyond incumbent-contractor familiarity. Supply side: a genuine intangible/know-how lead in compact cold-atom engineering — clocks, RF, gravimeters — but a lead is not a barrier: it is contestable (Vector Atomic — now inside IonQ; Microchip; Exail/Muquans; university spinouts), partially licensed from CU/WARF with government march-in rights, and out-spendable. Scale: none — sub-scale at $32.5M of revenue. The strongest moat-candidate is niche customer captivity in quantum sensing procurement: once Tiqker is designed into DoD PNT programs and NASA QGG, incumbency plus clearances plus ITAR create modest program stickiness — the weakest form of captivity, real but re-compete-exposed, and it protects a defense-niche revenue stream, not a quantum-computing prize.

Head-to-head, listed cohort (FY2025, per each company’s SEC filings):

Private rivals: Quantinuum (48 LQ, 99.92%, $10B pre-money Series C, ~$1.7B June 2026 IPO), Atom Computing (24 LQ with Microsoft, QBI Stage B), QuEra (96 LQ, QBI Stage B, NVentures-backed), Pasqal, PsiQuantum ($1.3B+). INFQ’s true differentiation inside this set is revenue realism: it is the only listed pure-play whose revenue is majority product/sensing rather than compute-science-project, and the market is paying far less for its compute option than for peers’ — arguably rational given mid-pack logical qubits and the QBI exclusion.

Open question with strategic upside: can Superstaq — hardware-agnostic, DARPA-HARC-selected, the only hardware vendor on the software track — become a switching-cost asset across other vendors’ hardware? Plausible; zero disclosed revenue evidence.

Verdict: no moat in the strict taxonomy; a defensible niche and a cheap option. The sensing franchise has real, narrow, procurement-shaped stickiness; the compute program is a mid-pack contender in an unsettled race against better-funded rivals, discounted by the USG’s own benchmark. INFQ is not “a cheap IONQ” — it is a sensing business with real revenue plus a cheap-ish option on neutral-atom compute, and should be analyzed as such.

5. Growth History and Forward Opportunities

History (SEC/audited): FY2023 revenue $10.9M → FY2024 $28.8M (+163%) → FY2025 $32.5M (+13%) → Q1-2026 $9.46M (+14%, “record Q1,” “100% organic”). Losses throughout: net loss −$52.8M (FY2023), −$53.8M (FY2024, including a $13.5M impairment), −$31.8M (FY2025), −$30.3M (Q1-2026, including $11.5M of one-time de-SPAC costs). The +163% in FY2024 was a step-change in milestone-based UK/US government awards (~$16.4M of new fully-funded milestone contracts, ~$9.4M UK), not a repeatable commercial motion — and FY2024’s UK contracts (~39% of revenue) then expired, costing ~$5.0M of FY2025 revenue. Q1-2026’s mix inverted: product revenue fell 51% while service revenue grew +232% on the NASA QGG ramp.

Growth quality: low. INTERPRETATION: the growth is real but government-milestone-driven, lumpy, gross-margin-compressing (Q1-26 ~21% vs ~41% y/y), and booked against a thin RPO (~$19.5M, of which $17.2M lands in 2026). The +23% guide (“at least $40M,” raised deliberately at Q1) is credible given the NASA QGG and APFIT ramps, but Q1 annualizes to ~$38M — the guide requires H2 acceleration in a milestone-recognized model. H2 award cadence is the swing factor for the year.

The forward drivers that are real, ranked:

1. Sensing productization — the only driver with commercial-economics potential. Tiqker PNT via the ~$11M APFIT fielding, the Safran channel (co-launched commercial timing product, April 2026), an Oxford innovation centre and UK manufacturing hub (opened May 2026), and follow-on DoD PNT procurement (DoW precise-timing procurement flagged on the FY2025 call; Golden Dome/MDA SHIELD IDIQ eligibility against “targeted spend up to $151 billion”).
2. NASA QGG Pathfinder and the gravity franchise it anchors. Sole-prime sensor position, $20M+ contracted to date, space-qualified path (Cold Atom Lab hardware on the ISS since April 2026). Follow-on phases could be large — or could not exist; the initial phase is what is contracted.
3. Sovereign/ally quantum infrastructure. UK NQCC (delivered the UK’s largest QC, cited in the UK’s £2B announcement), Illinois IQMP/NQAC (~$50M public-private partnership over four years, Infleqtion’s announced QC HQ, with a fault-tolerant Sqale deployment and Chicago Quantum Innovation Center announced July 2026), Japan Moonshot (only foreign QC partner), Australia. Lumpy but multi-$M each; computing system sales “could be tens and tens of millions” per sale (Kinsella, Q1-2026 call).
4. The policy stack as 2026 demand accelerant. The ~$100M Commerce CHIPS LOI (May 2026, part of $2.013B across nine companies, with a government equity stake), three DOE Genesis Mission projects (July 2026: Argonne, Brookhaven, LLNL with CU Boulder), the June 2026 quantum executive order, ARPA-E’s first-ever quantum computing contract (Feb 2026) and QC3 (only neutral-atom performer, April 2026).

The hype ledger — treat as hypotheses, not drivers: CML is marketed in AI-boom language but its revenue evidence is two ~$1–2M Army/Navy awards; QCaaS is self-described “very early stage”; the 1,600-atom array is a physical-qubit vanity metric; the NVIDIA relationship is non-exclusive ecosystem plumbing (NVentures backed rival QuEra); and the 100-logical-qubit-by-2028 roadmap is a plan, not a demonstration. The post-listing tape is itself a growth-funding consideration: with the stock below the $10 PIPE price and the resale registry running, the burn is financed from the $568.7M balance — genuinely ample — rather than new paper; solvency is not the issue, dilution-at-bad-prices is.

Verdict: real growth, low quality, genuinely visible catalysts. The base case for +23% in 2026 rests on contracted program ramps plus a normal H2 award season — achievable, but the mix shift it implies keeps pressure on margins, and nothing in the forward book yet converts the compute narrative into booked revenue.

6. Financial Quality

Reporting basis — read this first. The FY2025 Form 10-K (filed 2026-03-31) contains only the SPAC shell’s financials; Legacy Infleqtion’s audited FY2025/FY2024 statements and MD&A live in the 8-K/A filed the same day (KPMG, Denver, unqualified, auditor since 2022); FY2023 and 9M-2025 come from the S-4/A; the Q1-2026 10-Q (filed 2026-05-15) is the successor company on a reverse-recapitalization basis with Legacy Infleqtion as accounting acquirer. No goodwill or intangibles were created in the merger.

The P&L spine ($M):

(FY2024 includes the $13.5M Morton Photonics impairment; Q1-2026 includes one-time de-SPAC costs. Sources: 8-K/A 2026-03-31; S-4/A; Q1-2026 10-Q.)

The two fundamental-quality red flags. First, concentration: one customer was 61% of Q1-2026 revenue (the year-ago quarter had three customers at 51%/29%/10%), and government customers were 85%. Second, margin trajectory: gross margin halved y/y to 21.0% on mix shift toward lower-margin service/government development contracts. A company guiding to “at least $40M” on milestone-recognized government development revenue is guiding to a mix that compresses gross margin as it grows — the opposite of operating leverage.

The burn is smaller than the headlines — and ramping. Q1-2026’s reported OCF of −$19.2M includes ~$10.7M of one-time transaction costs paid at closing; the clean operating burn is ~−$8.5M, plus $0.3M capex → clean FCF burn ~−$8.8M/qtr (~$35M/yr). FY2025 clean FCF burn was −$26.5M. But the direction is up: R&D nearly doubled y/y, public-company SG&A is stepping up even ex-transaction-costs, and SBC of $8.3M in Q1 is the new run-rate, not a one-time item — new public-company grants at a $13.22 weighted grant price plus $45.2M unrecognized over 3.6 years implies ~$12M/yr for ~4 years. CFO guidance is for a “modest increase in cash burn from 2025 levels” with CapEx rising for US/UK innovation centers (Q1-2026 call). Watch the non-GAAP add-back categories, which expanded in Q1 to include go-public transaction expenses (a $20.4M GAAP-to-non-GAAP gap in the quarter).

The balance sheet is the strongest item in the file. At 3/31/26: cash $84.7M + available-for-sale securities $484.0M (US Treasuries $127.9M + corporate debt $356.0M) = total liquidity $568.7M; total assets $612.6M; total liabilities only $27.4M; stockholders’ equity $585.3M; no debt. Interest income of $3.2M in Q1 already offsets a meaningful slice of the clean burn. Runway: over a decade at the Q1 clean burn; ~7–8 years even if burn roughly doubles from here; management’s own statements (“at least 12 months,” 10-Q; “12 to 18 months,” 8-K/A MD&A) are boilerplate-conservative. Solvency is not a near-term risk in any scenario this memo can construct.

Dilution and the fully-loaded share count. Shares outstanding went from 216.47M at closing (2026-02-13) to 218.20M on the Q1 10-Q cover (2026-05-12) — +0.8% in one quarter, before any raise. Overhang inventory: 34.6M stock options at a $2.33 weighted-average exercise price (25.1M exercisable at $0.65 — deep in the money); 10.4M INFQ WS warrants at an $11.50 strike (the stock traded above $12 in April–June, so these are live); 33.4M shares reserved under the 2026 Equity Incentive Plan (~15% of shares out) plus an ESPP. Fully diluted is ~261M+ shares before future grants. The sector pattern (QBTS 266.6M→370.0M shares in a year; RGTI 133M→332M; IONQ +87% in under four years) is the base rate for what happens next.

Accounting and controls. KPMG has audited the operating company since 2022 with unqualified opinions — a genuinely better starting point than much of the cohort. Against that: the Q1-2026 10-Q discloses FOUR material weaknesses in ICFR (segregation of duties over journal entries; insufficient accounting personnel/risk assessment through 2025; monitoring controls over the UK subsidiary; IT general controls), with remediation that “may extend into 2027” — typical for a small private finance function post-de-SPAC, but a real flag for a company whose investment case depends on trusting milestone-revenue recognition. Positively, the usual de-SPAC GAAP noise does NOT recur: warrants and the founder earn-out are equity-classified, so no fair-value remeasurement flows through the successor P&L post-Q1-2026. (The FY2025 SPAC-shell 10-K’s −$66.9M net loss was a non-cash PIPE subscription-agreement mark — none of it is Infleqtion operating performance.)

Verdict: a fortress balance sheet attached to a low-margin, concentrated, milestone-driven P&L whose losses are structurally widening as the R&D program scales. The financial quality story is not “will they run out of money” — they will not, for years — it is “what does each new dollar of revenue cost, and how many new shares does the comp plan mint while we find out.”

7. Capital Allocation

The de-SPAC itself: shareholder-friendly by the standards of the species. FACT: the merger struck a $1.8B equity value, all stock at $10.00/share; the $126.5M PIPE was priced flat at $10.00 with no discount and no warrants, signed with the merger agreement (2025-09-08); redemptions were 37,821 shares — 0.09% — so essentially the entire $414M trust survived to close; gross proceeds were ~$528.2M (trust $401.6M net + PIPE $126.5M) against ~$35.8M of total transaction costs (10-Q Note 3; 8-K/A MD&A). Kinsella’s “raised $516 million in net proceeds with virtually no redemptions” (FY2025 call, 2026-04-08) is accurate. The sponsor’s economics were standard-issue — Michael Klein’s Churchill Sponsor X: 10.65M shares at an effective ~$0.28/share (~$106M at $10 on ~$3M invested) — but modest at 4.9% of the pro forma company, and only 1.5M founder shares carried an earn-out, which already triggered in April 2026. Post-close ownership: legacy Infleqtion holders 70.1%, CCX public 19.1%, PIPE 5.8%, sponsor 4.9%.

The pre-merger track record: mixed. Legacy Infleqtion raised ~$285.4M of venture preferred (Seed through Series C-1, final close May 2025) from Maverick Capital, LCP Quantum, Global Frontier, BOKA Group, S&G Foundation and others. Its two acquisitions — Morton Photonics (2024, $3.0M net cash plus contingent consideration) and SiNoptiq (2024, $2.7M) — were substantially written off within a year ($13.5M FY2024 impairment). INTERPRETATION: a science organization that was better at raising grants and venture rounds than at buying companies.

Post-listing deployment: conservative to a fault. No ATM, no follow-on, no debt, no dividends or buybacks contemplated. Deployment so far: $444.2M into AFS Treasury/corporate securities (yielding $3.2M of interest income in Q1) and de minimis capex ($0.3M/qtr). INTERPRETATION: with a $568.7M hoard and a ~$35M/yr clean burn, the treasury book is rational capital preservation — but it also means shareholders are paying ~$1.6B of EV for an operating business whose owner is mostly compounding at Treasury-plus-corporate yields.

The float machinery is the capital-allocation story of 2026. The resale S-1 (filed 2026-03-31, effective 2026-04-09) registered ~121.8M resale shares — legacy holders 98.4M + PIPE 12.65M + founder 10.35M + sponsor private-placement 0.3M — plus 10.4M warrant-exercise shares: more than 60% of the company made resalable within two months of listing. The 180-day lockup (nominal expiry ~2026-08-12) carried an early-release trigger — VWAP ≥ $12.00 for 15 of 180 trading days — that was satisfied by ~April 2026 (the 10-Q confirms the identical founder earn-out trigger as met; the lockup release date is a high-confidence inference, not an explicit disclosure). Five 424B3 resale prospectuses followed in 14 weeks (04-10, 05-14, 05-15, 06-08, 07-15).

The insider record: 100% sell, 0% buy. Across all 55 Form 3/4 filings since listing there is not one open-market purchase. The dispositions: Maverick Capital sold 16,776,890 shares for ~$262.5M at $14.69–$17.91 between 2026-05-21 and 05-29 — not under a 10b5-1 plan — going from 9.2% at closing to ~1.5%, while its managing partner David B. Singer sits on the board. CEO Kinsella exercised 545,824 options at $0.90 and sold ~769,954 shares for ~$13.1M at $15.44–$18.17 (2026-05-22). CTO Gokhale sold 120,000 at $17.73 (06-04); CRO Lipman ~$1.6M; director Kristina Johnson ~$0.85M. Two other VCs exited by in-kind distribution rather than sale: LCP Quantum distributed its entire ~27.7M-share position to LPs (04-22) and Global Frontier cut 25.6M → 2.4M shares the same way (13G/A, 06-09). In total, >40M shares — ~19% of the company — changed hands or became freely sellable in April–June 2026. INTERPRETATION: these are largely VC fund-cycle exits with LP obligations, not necessarily information-driven — but the CEO selling ~$13M within three months of listing, a board member’s fund selling ~84% of its position, and zero insider stepping in at $10 is a soft-negative signal on near-term conviction that no amount of “fund lifecycle” framing fully erases.

Incentive structure. The 2026 Equity Incentive Plan reserves 33.4M shares (~15% of shares out) plus an ESPP; legacy options (34.6M at $2.33 WAEP) were assumed at close; new-hire RSUs to the CFO and CLO granted May 2026. Kinsella holds 5.95M options plus ~0.7M shares (~3.9% beneficial). INTERPRETATION: a heavy equity-comp culture that will keep diluting — and a board where Churchill (Klein; Nicholas Johnson, appointed May 2026) and Maverick (Singer) retain seats while their economic exposure shrinks.

Marathon lens on the company itself: Infleqtion did the cycle-rational thing — it converted narrative into a $568.7M fortress at the top of the funding window with near-zero redemptions. The cohort base rate says the next act is serial issuance; INFQ’s balance sheet says it does not need one for years. Which of those two governs is the capital-allocation question to watch.

Verdict: a well-executed deal, a conservative treasury, a mixed M&A history, and an insider register that reads as distribution. The capital-allocation risks are not solvency or reckless deployment — they are the unusually large, rapidly-freed float and a comp culture with ~60M shares of options, warrants and plan reserves queued behind a $10 stock.

8. Changes and Headwinds — Last Two Years

Structural changes.

• Private → public via de-SPAC (the defining change). ColdQuanta d/b/a Infleqtion became INFQ on 2026-02-17 with ~$528M gross proceeds, a new executive team (Kinsella/Gokhale/Hart/Lipman), a NYSE listing, and a 121.8M-share resale registry. The reporting entity, equity plan, SBC run-rate (~$12M/yr) and control environment are all new.
• Leadership. Matt Kinsella (ex-Maverick Ventures MD; first investor 2018; board since 2018) became CEO in April 2024 — an investor-CEO, not a founder-scientist; the notable in-window addition is Dr. Joseph Buck (ex-Lockheed Martin senior fellow, Caltech neutral-atom PhD) as SVP Quantum Computing Systems leading Sqale (July 2026).
• From UK-weighted to US/sovereign-diversified revenue. FY2024’s revenue was ~39% UK contracts that expired (a ~$5M FY2025 headwind); the mix has since rebalanced to ~60% US government, ~12% UK, ~6% Australia (FY2025), with Japan and Illinois added.
• The policy stack arrived. Golden Dome/SHIELD IDIQ eligibility, the ~$100M Commerce LOI with a government equity stake, the June 2026 executive order, three DOE Genesis Mission projects, the UK’s £2B commitment — the 2026 demand environment is materially more favorable than 2024’s.
• Compute credibility markers. The 12-logical-qubit demonstration and first Shor’s-algorithm-with-logical-qubits paper (Sept 2025); the 1,600-atom array (Dec 2025); NVIDIA NVQLink/Ising-model integrations; DARPA HARC (Apr 2026).

Headwinds.

• The DARPA QBI Stage-B exclusion (Nov 2025) — both neutral-atom rivals advanced; Infleqtion did not. The single largest narrative vulnerability.
• The supply overhang. Early lockup release (~Apr 2026), five 424B3s, ~16.8M Maverick shares sold, ~50M VC shares distributed in-kind, ~$18M of executive sales, and the formal 180-day expiry (~2026-08-12) still ahead at the report date — thirteen days out, the same day as Q2 earnings.
• Margin and mix deterioration. Gross margin 40.7% → 21.0% y/y in Q1; product revenue −51%.
• Customer concentration. One customer at 61% of Q1 revenue; ~85% government overall; all of it terminable for convenience.
• Control weaknesses. Four ICFR material weaknesses with remediation possibly into 2027.
• Sentiment beta. Beta ~4.4, realized vol ~118%, ~13% short float (+29.6% m/m), RS_YTD −44%; the stock trades as a sector basket instrument — the “Space & Quantum Innovators” basket rose +7.8% over the trailing 63 days while INFQ fell ~25%: idiosyncratic, de-SPAC-specific underperformance on top of sector beta.
• No short-seller report has been published on INFQ (negative search, 2026-07-30) — the bear case is supply and validation, not fraud allegations.

Verdict: the two-year delta is genuinely positive on fundamentals and genuinely negative on structure. The company is bigger, better funded, better validated by sovereign customers, and better led than in 2024 — and its stock trades below the SPAC trust value it debuted above, because the de-SPAC machinery converted a strong operating story into a weak supply story.

9. Risk Analysis (Risk Matrix)

Reading the matrix. The dominant risks are supply and validation, not solvency — the inverse of most of the cohort, where financing risk leads. The $568.7M unlevered liquidity pile makes a total loss implausible absent fraud or reckless deployment; the realistic bear outcome is multiple compression toward the cash-plus-contractor floor, not a wipeout. The risks cluster in time: the ~2026-08-12 lockup-expiry/Q2-print double event is where supply, execution, and sentiment risks all land at once.

10. Valuation Discussion (Embedded Expectations)

Data integrity first. FactorsToday’s market cap ($1,926.7M) implies ~193M shares — stale; the 10-Q cover count is 218,196,891 (2026-05-12), which yfinance confirms. yfinance’s EV field ($1,488M) does not reconcile to its own cash figures (the known yfinance-EV trap) — discarded. AZI’s valuation_index returns null for INFQ (141 trading days is below model minimums); there is no own-history percentile to report. Everything below is hand-built from EDGAR XBRL and filings.

The bridge (2026-07-30, $9.98):

• Market cap: 218.2M shares × $9.98 = ~$2.18B
• Less: total liquidity $568.7M ($84.7M cash + $484.0M AFS; debt ~$4.9M lease-scale) → net cash ~$2.6/share ≈ 26% of the price
• Ex-cash EV ≈ ~$1.61B ≈ ~$7.4/share — ~74% of the price is “option value” on the quantum business
• Revenue: FY2025 $32.5M; TTM $33.7M; FY2026 guide “at least $40M”
• Multiples: EV/TTM sales ~48x; EV/FY26E sales ~40x; market cap/TTM sales ~65x; market cap/net cash ~3.8x

Conventional valuation is meaningless; the honest frame is sum-of-the-parts. P/E is undefined, EV/EBITDA is negative, DCF requires forecasts the company cannot credibly furnish. The security decomposes into: (1) ~$2.6/share of net cash — liquid, investment-grade, real; (2) a sensing/government-contracting business with ~$33.7M TTM revenue growing low-teens-to-+23%, 21–36% gross margins, and cost-plus economics — worth a defense-contractor multiple, call it 2–4x sales, or very roughly $0.1–0.15B on its own; and (3) a call option on neutral-atom quantum computing (12 logical qubits, a 2028 roadmap, excluded from QBI Stage B) plus the ~$100M Commerce LOI. At ~$1.61B of EV, the market is paying ~$1.5B for pieces (2) and (3) combined — i.e., almost all of the EV is the compute option and the policy premium.

The cohort comparison cuts both ways — and the Lead’s obligation is to explain the discount, not assume mispricing. On EV/Sales INFQ is the cheapest listed pure-play by an order of magnitude: ~48x TTM versus IONQ ~148x trailing (~72x forward), RGTI ~640–900x, QBTS ~650x, QUBT ~950x. It has the second-largest revenue base ($33.7M TTM vs IONQ’s $130M; all others ≤$12M), positive growth, and the second-most cash relative to market cap (~26% vs QUBT’s ~72%; RGTI/QBTS ~8–9%). The market is pricing INFQ as the value name of a fantasy-valued cohort. The reasons are identifiable and mostly rational: (i) its revenue is government/sensing-shaped, not compute — the market pays for compute dreams, not cost-plus clocks; (ii) it is a five-month-old de-SPAC with a mechanical supply overhang peers have already digested; (iii) it lacks a retail cult following and a validated technical milestone (QBI exclusion); (iv) mid-pack logical qubits. Cheap-relative-to-peers and expensive-relative-to-any-fundamental-anchor are simultaneously true.

Embedded expectations. ~$1.61B of ex-cash EV is ~40x the FY26E $40M. Reverse the multiple: at a generous 20x forward sales the price embeds ~$87M of revenue (2.2x the guide); at 10x, ~$174M (4.3x). The tape requires Infleqtion to roughly double-to-quadruple revenue over the next few years while not blowing the runway — a dramatically lower bar than RGTI (~45x revenue needed) or QBTS (~33x), but still pure TAM underwriting: the Commerce LOI (a letter, not a contract), the sovereign testbed pipeline, and the NVIDIA work must convert to booked, recognized revenue.

Scenario frame (assumptions explicit; values, not targets):

• BEAR ~$3.7/share (−60%+): quantum-winter sentiment; government awards stall; revenue plateaus at $35–40M; the multiple compresses to ~10x sales → EV ~$0.35–0.40B plus cash ≈ ~$0.8B equity. Assumes the LOI never converts and burn stays ~$77M/yr. Arithmetically, even at zero operating value the net cash alone is ~$2.6/share — the bear case is mostly multiple compression, not impairment.
• BASE ~$8/share: FY26 guide met; 25–30% CAGR to ~$65M FY27 / ~$85M FY28; holds ~15x forward sales → EV ~$1.3B plus cash ≈ $1.7–1.8B equity. INTERPRETATION: the current price roughly discounts successful execution of the base case, with modest dilution already assumed — the market is not giving the compute option away, but it is not charging IONQ prices for it either.
• BULL ~$16/share: the Commerce LOI converts to funded programs; the NVIDIA/logical-qubit work scales into commercial hybrid quantum-AI revenue; ~$150M+ revenue by 2029 at ~20x → EV ~$3B+ plus cash. The $11.50 warrants return in-the-money, adding tens of millions of shares but also cash. The load-bearing assumption — neutral-atom reaches useful scale within the decade — is unproven.

No price target, no recommendation — this section describes embedded expectations and scenarios only. The judgment call lives solely in Claude's Take above.

11. Variant Perception

Consensus belief. The sell-side that covers the name is bullish-thematic: consensus PT ~$20.67 (three analysts; Citi Buy $20, BTIG Buy $22 — both citing the NVIDIA collaboration; Canaccord high $22), with nine banks on the calls (Citi, BTIG, Craig-Hallum, Wedbush, Cantor, JPMorgan, Canaccord, Rosenblatt, Needham). The tape, meanwhile, is voting the opposite: −44% YTD, −53% off the April high, below the $10 PIPE price, 13% short float and rising. The retail/momentum base treats INFQ as the newest, cheapest quantum lottery ticket; fundamental holders are being asked to absorb venture-capital inventory. The short interest (+29.6% m/m) says a growing cohort is explicitly betting the supply is not done.

Strongest bull case. You are buying the only listed neutral-atom company — the modality with the strongest recent scientific momentum (QuEra’s 96 logical qubits in Nature) — at the cohort’s cheapest multiple, with the cohort’s second-largest and fastest-organic revenue base, a $568.7M no-debt balance sheet that funds the roadmap for years, a real sensing franchise (Tiqker/APFIT/Safran/NASA QGG) that peers simply do not have, and a policy tailwind (the $100M Commerce LOI, Golden Dome eligibility, DOE Genesis, UK £2B) that is converting quantum from science project to national infrastructure. The de-SPAC supply is finite and largely already distributed; once the registry clears and the 8/12 overhang passes, the scarcity bid returns to the only neutral-atom ticker. Bear-to-bull here is a re-rating, not a miracle: the stock was $19.87 on 2026-06-02.

Strongest bear case. It is a defense R&D contractor with a quantum-computing press-release operation: 85% government revenue, one customer at 61%, a ~$19.5M backlog against a $40M guide, gross margin halving to 21%, mid-pack technology excluded from the USG’s own utility-scale benchmark, and an insider register that is 100% sell — including the board member’s own fund liquidating ~84% of its position and the CEO cashing ~$13M within three months of listing. The Marathon capital cycle says the whole cohort mean-reverts toward negative fundamentals; when it does, the multiple that compresses hardest is the one attached to the weakest technical story. The base-case scenario value (~$8) is below the current price.

The 3–5 assumptions that actually matter.

1. Does the Commerce LOI convert to a definitive, funded contract? (The difference between a policy press release and revenue; bull needs yes.)
2. Does the 2026 guide hold? (Q1 annualizes below “at least $40M”; the year is H2-weighted on new awards; a guide cut at the 8/12 print breaks the revenue-realism thesis that justifies the relative premium to RGTI/QUBT.)
3. Does the supply actually clear after ~2026-08-12? (If new 424B3s keep landing and insider selling resumes, the falling-knife read is confirmed.)
4. Does Infleqtion re-enter DARPA QBI (Stage-A abstracts due 2026-07-31) and hold the 30-logical-qubit 2026 milestone? (The validation gap is the discount’s technical justification.)
5. Does sector sentiment survive the Quantinuum IPO and the next quantum-winter headline? (Beta 4.4 means the sector decides INFQ’s quarter before INFQ does.)

What would falsify each side. Bull is falsified by: a guide cut or Q2 miss on 8/12, the LOI lapsing unconverted into 2027, failure to re-enter QBI, resumed insider selling post-expiry, or gross margin stuck near ~20%. Bear is falsified by: LOI conversion to a funded award, two consecutive quarters of guide-beating revenue with RPO rebuilding, QBI Stage-A selection, insider open-market buying at ~$10, or a technical milestone (30 logical qubits on schedule) that closes the validation gap with Atom/QuEra.

Factor-positioning read. With 141 trading days of history, no stable factor loadings exist (FactorsToday returns null across loadings/leaderboard/specific-vol) — itself a fact: this is a price-discovery security with no established factor identity, dominated by idiosyncratic supply events and sector sympathy. The marginal price-setter is flow — VC inventory out, thematic retail in — not DCF. The variant-perception opportunity, if there is one, is precisely timing the end of the mechanical supply against the start of fundamental proof: the market is currently paying you nothing for waiting early, and the 8/12 double event is the first date on which both sides of that trade get new information.

12. Fact vs. Interpretation Table

13. Open Questions

1. Has the ~$100M Commerce CHIPS LOI converted to a definitive agreement — and on what terms does the government equity stake price? No post-May 8-K located. This is the single largest pending fundamental data point.
2. Did Infleqtion apply to the new DARPA QBI Stage-A solicitation (abstracts due 2026-07-31)? Re-entry would materially repair the validation narrative; absence would deepen it.
3. What happened to the “~$50M booked and awarded business by YE2025” de-SPAC metric? Never restated post-listing; reconcile against FY2025 revenue ($32.5M) plus contract liabilities — and against the QBTS-report critique of swing-prone bookings metrics.
4. What are Tiqker’s unit economics? Price point, units shipped, gross margin — undisclosed; the sensing franchise cannot be valued precisely without them.
5. What is the H2-2026 award cadence required to reach “at least $40M,” and how much is already in hand? The 8/12 Q2 print is the first checkpoint.
6. What are the Illinois $50M partnership’s conversion milestones and revenue-recognition shape, and what is the public/private split?
7. What is Maverick’s residual position (~3.2M shares estimated) and do distributed VC shares (LCP ~27.7M, Global Frontier ~23M) keep hitting the tape after 2026-08-12? The next 13D/A and Form 4s answer whether the supply truly clears.
8. What does the $100M-LOI government equity stake imply for share count, governance, and future procurement preference? Equity-taking governments are a new phenomenon in this sector; the precedent terms matter.
9. Does the 2026 logical-qubit milestone (30) land on schedule — and does any independent benchmark of Sqale emerge? No third-party benchmark of the system currently exists.

14. What Must Be True

Bull case — for INFQ to re-rate toward and beyond the cohort’s multiples, the following must broadly hold:

• The Commerce LOI converts to a definitive funded program (8-K event), and the policy stack (Golden Dome, DOE Genesis, UK £2B) turns into booked, recognized revenue rather than letters.
• The 2026 guide of “at least $40M” is met or beaten with RPO rebuilding — proving the revenue base is programmatic, not a sequence of one-off milestones.
• The technical roadmap holds: 30 logical qubits in 2026 on the way to 100 by 2028, plus re-entry into DARPA QBI, closing the validation gap with Atom Computing and QuEra.
• The sensing franchise scales commercially: APFIT fielding converts to program-of-record procurement, the Safran channel generates recurring product revenue, and gross margin recovers from 21% toward the mid-30s.
• The supply clears: no new 424B3 cadence post-August, insider selling stops, and distributed VC shares are absorbed.

Bull falsification test: if, by year-end 2026, the LOI remains unconverted, revenue guidance is cut or missed, QBI re-entry fails, or new resale registrations keep landing — the “cheapest in cohort” discount is a value trap’s price, not a mispricing, and the bear scenario (~$3.7) governs.

Bear case — for INFQ to de-rate toward its cash-plus-contractor floor, the following must hold:

• Quantum-winter sentiment returns (the sector’s June spike already fully reversed) and cohort multiples compress toward revenue reality; INFQ’s ~48x TTM EV/Sales has the least distance to fall but falls with the group.
• Government awards stall or slip: the LOI lapses, H2-2026 awards disappoint, the “at least $40M” guide is cut at the 8/12 print.
• The validation gap widens: Atom/QuEra/Quantinuum extend their logical-qubit leads, QBI Stage B proceeds without Infleqtion, and the 30-qubit milestone slips.
• The overhang persists: more 424B3s, resumed insider/VC selling after the 8/12 expiry, and dilutive issuance at single-digit prices if the R&D ramp accelerates.

Bear falsification test: if Infleqtion converts the Commerce LOI to funded revenue, beats the guide with a rebuilding backlog, re-enters QBI, and insiders begin open-market buying near ~$10 — the falling-knife/supply thesis is broken and the stock deserves a re-rating toward at least its own base scenario (~$8) and plausibly the bull zone (~$16).

The pivot both cases share: everything above the ~$2.6/share net cash and a defense-contractor value for the sensing business is a judgment on whether government-funded quantum demand converts from letters and milestones into programs of record — and whether the registry of de-SPAC supply is finally empty. Both questions get their next answers on 2026-08-12.

Sections 1–15 contain no investment recommendation and no price target; the Claude's Take block at the head of this article is a clearly-labelled exception and represents the author’s own subjective opinion. General information only — not investment advice.

APPENDIX A — Standard Diligence Questionnaire

Infleqtion, Inc. (NYSE: INFQ) · Report date 2026-07-30

Answers are labeled Fact / Interpretation / Assumption where it matters. Where a question does not map to Infleqtion’s business model, the correct analog is given. Reporting-basis caution throughout: the FY2025 Form 10-K contains the SPAC shell’s (CCX) financials; Legacy Infleqtion’s audited FY2025/FY2024 statements are in the 8-K/A filed 2026-03-31 (KPMG); Q1-2026 is the successor company on a reverse-recapitalization basis.

General

What thoughtful questions have other investors asked about this company? From the two post-listing earnings-call Q&As (FY2025 call 2026-04-08; Q1-2026 call 2026-05-14): (1) What should the KPIs be? — JPMorgan (Peter Peng) asked which metrics signal things are on track; Kinsella named exactly two: execution against revenue guidance and logical qubits. (2) How does the $40M guide decompose? — BTIG asked for the sensing/computing and software/hardware split; management declined beyond “roughly 2/3 sensing, 1/3 computing, wide error bars.” (3) What is the conversion rate on the $300M+ pipeline cited at the 2026-03-11 Analyst Day — Citi (Atif Malik); management declined to give one. (4) What underpins the raised guide (“at least $40M”) — Citi asked whether QGG is driving the implied H2 acceleration and what the linearity looks like; the answer leaned on “broad-based demand,” and Q1’s $9.5M annualizes to only ~$38M. (5) Why not spend more? — Wedbush pressed whether the low-burn posture should give way to stepped-up R&D/S&M now that the company is public and flush. (6) Golden Dome — Cantor Fitzgerald (Troy Jensen) noted the administration has not fleshed out the program and asked what the SHIELD IDIQ eligibility (targeted spend “up to $151 billion”) actually means. (7) Physical vs logical qubit trade-off — BTIG follow-up on scaling array size vs error rates. (8) Is Quantum Spectrum new or a SqyWire iteration? — Craig-Hallum. (9) Hype vs reality in the NVIDIA relationship — Canaccord asked directly about depth of the integration (answer: Ising AI models for calibration and error-correction decoding; a collaboration, not an investment or exclusivity). (10) What does it take to commercialize Quantum Spectrum (price points, timeline) — Rosenblatt; and government vs commercial mix — Needham. (11) Does the platform cross-sell in practice? — Wedbush. The unasked-but-central question is the one the filings answer for free: with the lockup released and five resale prospectuses in 14 weeks, who is selling, and why is no insider buying at $10?

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Not applicable — pre-profit. Infleqtion has never earned an operating profit (FY2023 net loss −$52.8M; FY2024 −$53.8M; FY2025 −$31.8M; Q1-2026 −$30.3M). The correct cyclical analog is the government funding cycle and contract cadence: revenue is ~85% government, milestone/percent-complete recognized (91% over-time in Q1-2026), on contracts terminable for convenience. FY2024’s +163% was one cohort of UK/US awards; when the UK contracts (~39% of FY2024 revenue) expired, it cost ~$5.0M in FY2025. That is the cycle that matters, and it turns on appropriations, program re-competes, and award timing — not end-market demand.

Driven by external environment or internal actions? Predominantly external. Revenue depends on government program decisions (NASA QGG, APFIT, UK NQCC, Commerce CHIPS, sovereign programs); the stock price is driven overwhelmingly by external sector sentiment (beta ~4.4; realized vol ~118%; +31.5% on 2026-05-21 purely on a sector-wide government-funding day). Internal levers — R&D pace, sensing productization, the Safran channel — are real but second-order to the funding environment.

How stable are revenues? Fact. Unstable and lumpy: $10.95M → $28.84M → $32.5M (FY2023–25), Q1-2026 $9.46M with product revenue down 51% y/y offset by service +232% (mostly the NASA QGG ramp). One customer was 61% of Q1-2026 revenue. Remaining performance obligations at 3/31/26 were only ~$19.5M against a $40M guide — roughly half the year must still be booked-and-billed. No meaningful recurring base: QCaaS is self-described “very early stage”; software (Superstaq) is small.

Outlook for products/services? Fact/Interpretation. Guidance is $40M for 2026 (+23%), hardened from “approximately” to “at least” between calls — a raise, with management flagging the change as deliberate. Credibility rests on NASA QGG/APFIT ramps and is heavily H2-weighted. The 100-logical-qubit-by-2028 roadmap and QCaaS consumption are optionality, not drivers.

How big will this market be? Growing or shrinking? Domestic or international? Interpretation. Growing, but off a tiny base, with the company’s own 10-K citing third-party forecasts ~14 years out (~$130B quantum computing, ~$30B quantum sensing by 2040 — a fantasy-grade forecasting horizon). Current sector-wide commercial revenue is a few hundred $M globally; the listed pure-play profit pool is negative. Revenue today is ~70% U.S., ~13% UK, ~11% APAC (FY2025) — international in footprint (UK NQCC, Japan, Australia, ESA) but everywhere government-anchored. The quantum sensing niche (PNT, RF, gravity) is the nearer-term, genuinely procurable market — smaller, defense-procurement-shaped, and contested.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Fact/Interpretation. More — sharply. ~$6.3B of private quantum capital raised in the trailing ~12 months; Quantinuum’s ~$1.7B IPO (June 2026) adds a newly flush rival; Xanadu de-SPAC’d at $3.6B; Google opened a formal neutral-atom group (March 2026); both of Infleqtion’s direct neutral-atom rivals (Atom Computing, QuEra) — not Infleqtion — were advanced to DARPA QBI Stage B (Nov 2025). INFQ’s float demand partly reflects scarcity: it is the only listed neutral-atom pure-play.

How profitable is the business (ROIC, ROE)? Fact. Negative on any honest measure — there are no positive returns to compute a ratio on (FY2025 op loss −$35.3M on $32.5M revenue; Q1-2026 clean operating burn ~$9M/qtr). Pre-merger stockholders’ deficit was −$208.2M with a $231.1M accumulated deficit. Conventional ROIC/ROE are not meaningful; interest income on the ~$569M cash pile is a treasury return, not a business return.

How profitable is the industry — competitors, barriers to entry? Fact. No listed pure-play earns an operating profit anywhere in the sector; the aggregate profit pool is negative and funded by capital markets and government, not customers. Barriers are high on technology and talent (neutral-atom physics talent is a small, contested pool) but low on capital right now — the market funds anyone with a quantum story. That combination (Marathon capital-cycle late stage) historically produces poor cohort-level equity returns.

Can the business be easily understood? Half. The sensing franchise (optical clocks, RF and inertial sensors sold into defense PNT programs) is an understandable defense-electronics business. The computing line (neutral-atom fault-tolerant QC) is highly specialized, years from commercial validation, and its frontier claims (1,600-atom array, 12 logical qubits, 99.73% CZ fidelity) cannot be independently benchmarked by an investor — the modality’s best-published results sit with private rivals (QuEra 96 logical qubits, Nature Jan 2026).

Undermined by foreign low-cost labor? No — the binding input is scarce physics talent (205 employees, >160 physicists/engineers, ~55% Denver metro, JILA/CU-Boulder heritage), contested by Quantinuum/Atom/national labs, not wage arbitrage. ITAR/security-clearance requirements on the government book are a mild protective barrier against foreign competition.

Do brands matter? No consumer brand. What matters is program reputation with government buyers (NASA prime position on QGG, UK NQCC delivery, APFIT fielding) and credibility signals (NVIDIA ecosystem, DARPA HARC software-track selection). “Brand” here is procurement track record.

Nature of competition? Switching costs? Fact/Interpretation. Competition is technological (which modality reaches fault tolerance first — and Infleqtion is mid-pack on the metric that matters: 12 logical qubits vs QuEra 96, Quantinuum 48, Atom 24) and procurement-reputational. Switching costs are near zero in compute (cloud backends are one recompile away) and low-to-modest in sensing: government contracts re-compete and are terminable for convenience, though design-in incumbency, clearances, and ITAR create some program stickiness — the weakest form of customer captivity, protecting a defense-niche revenue stream, not a quantum-computing prize. Greenwald verdict: no durable competitive advantage; the cold-atom engineering lead is a lead, not a barrier (contestable, partially licensed from CU/WARF with government march-in rights, out-spendable).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Fact/Interpretation. The real assets are off-book by accounting convention: ~$285M of expensed R&D cumulative, the patent portfolio (deepest in cold-atom systems per the 10-K), the CU/WARF licenses, and the Boulder team’s know-how — none carried at value. Conversely, there is no hidden hard asset: the merger created no goodwill (reverse recapitalization; CCX net assets at historical cost), and FY2024’s $13.5M impairment already flushed the Morton acquisition intangibles.

Off-balance-sheet liabilities? Minimal and disclosed: ~$2.4M remaining Morton contingent consideration (milestones to Jan-2028), leases-scale obligations (yfinance total debt ~$4.9M). Critically, the 10.42M warrants ($11.50 strike) and the founder earn-out are equity-classified — no derivative liability, no future fair-value P&L noise. The 1.5M-share earn-out trigger (VWAP ≥ $12) was already met in April 2026.

How conservative is the accounting? Interpretation — mixed, trending toward watch-list. Positives: KPMG audit (unqualified, auditor since 2022); plain revenue recognition on milestone contracts; the de-SPAC was structured cleanly (equity-classified warrants, no earn-out liability). Negatives: four ICFR material weaknesses disclosed in the Q1-2026 10-Q (segregation of duties over journal entries; insufficient accounting personnel/risk assessment; UK subsidiary monitoring controls; IT general controls), with remediation that “may extend into 2027” — typical small-private-company post-de-SPAC hygiene, but a real audit-risk flag. Also: non-GAAP add-back categories expanded in Q1-2026 to include go-public expenses ($20.4M GAAP-to-non-GAAP gap); and the SPAC-era “~$50M booked and awarded business by YE2025” marketing metric was never restated post-listing (FY2025 actuals: $32.5M revenue + $6.9M contract liabilities) — a disappearing metric that argues for discounting promotional figures.

How CapEx-hungry is the business? Fact. Very light today: capex $2.9M (FY2024), $2.4M (FY2025), $0.3M (Q1-2026) — the model is R&D- and people-intensive, not asset-intensive. Management guides CapEx rising modestly for the US/UK innovation centers (Colorado, Oxford, Chicago/Illinois). No fab-scale capital requirement is currently planned or disclosed.

Capital Allocation & Management

How much FCF does the business generate, and how is it used? Fact. FCF is negative — a burn story, not a generation story. FY2025: OCF −$24.1M, capex −$2.4M → FCF ≈ −$26.5M. Q1-2026: OCF −$19.2M including ~$10.7M one-time de-SPAC costs → clean burn ≈ −$8.8M/qtr (~$35M/yr), now ramping (R&D +93% y/y; public-company SG&A step-up; SBC at an $8.3M/qtr run-rate). Deployment so far: $444.2M parked in Treasuries/IG corporate bonds ($3.2M interest income in Q1), the rest into R&D and the roadmap.

Capital-allocation philosophy? Interpretation. Revealed by action: fund the science through the equity window while it is open. The de-SPAC itself is the defining capital event — and by de-SPAC standards it was unusually shareholder-friendly: ~$528.2M gross ($401.6M trust + $126.5M PIPE), $518.9M net proceeds, 0.09% redemptions (essentially the whole $414M trust survived), PIPE at $10.00 flat with no discount or attached warrants, and a small 1.5M-share sponsor earn-out (already triggered). Against that, sponsor economics were the standard promote: Churchill Sponsor X (Michael Klein) paid ~$3.03M for 10.65M shares (~$0.28/sh) worth ~$106M at $10 — a ~20% promote on the trust, though only 4.9% of the pro forma company.

Significant acquisitions recently? Fact. None in-window. Track record: Super.tech (2022 — brought the Superstaq software line and CTO Gokhale; strategically valuable), Morton Photonics (2024, $3.0M — substantially written off within a year via the $13.5M FY2024 impairment; $2.4M contingent consideration still outstanding), SiNoptiq asset deal (2024, $2.7M). Mixed record; the one software deal worked, the hardware deal did not.

Buying back shares? No — none contemplated; no dividends either.

Issuing shares to insiders? Fact. Yes, structurally: 34.6M legacy options outstanding at a $2.33 weighted exercise price (25.1M exercisable at ~$0.65, deep ITM); a new 2026 Equity Incentive Plan reserving 33.4M shares (~15% of shares outstanding) plus an ESPP; RSUs to the CFO (338,983) and CLO (211,864) in May 2026; $45.2M unrecognized SBC over ~3.6 years (~$12M/yr). Fully diluted ≈ 261M+ shares before future grants. No primary raise since listing (not needed — ~5.7-year runway), but the equity-comp culture guarantees steady dilution.

Insider transactions? Fact — the loudest signal in the file. Since the lockup’s early release (~April 2026, VWAP trigger met): zero open-market insider purchases. Maverick Capital (board member David Singer’s fund) sold 16,776,890 shares for ~$262.5M at $14.69–17.91 (May 21–29, not under 10b5-1), going from 9.2% to ~1.5% within 14 weeks of listing. CEO Kinsella exercised at $0.90 and sold ~770K shares for ~$13.1M (May 22); CTO Gokhale sold ~$2.1M; CRO Lipman ~$1.6M; director Johnson ~$0.85M. Separately, LCP Quantum distributed its entire ~27.7M-share position in-kind to LPs (April 22) and Global Frontier distributed ~23M shares in-kind (to 1.1%) — >40M shares (~19% of the company) sold or made freely sellable in April–June, the mechanical story behind the −44% YTD. No insider stepped in to buy on the slide from $18 to $10.

Compensation policy / motivations of management? Fact/Interpretation. Equity-loaded (options assumed at ~$2.33 WAEP; new 15% plan; CEO holds 5.95M options + ~0.7M shares, ~3.9% beneficial). The VC selling is partly mechanical fund-cycle exit (Maverick/LCP/Global Frontier are legacy private-round holders with LP obligations), not necessarily information-driven. But a CEO monetizing ~$13M within three months of listing, a board-seat fund selling ~84% of its position, and zero insider buying at $10 read as weak near-term conviction from the people who know the asset best. Governance watch item: two Churchill-linked directors plus Maverick’s Singer remain on the board while their economic exposure shrinks.

Valuation & Market Data

ADR / MLP / K-1? No — plain U.S. C-corp common stock on NYSE (INFQ), plus public warrants (INFQ WS / INFQ-WT, $11.50 strike, currently out-of-the-money). Standard 1099 treatment; no partnership or foreign-withholding complications.

Dividend policy? None, and none contemplated for the foreseeable future — a pre-profit company burning cash. All returns are price-driven.

How profitable is the business? Not — see the Competitive Position section. FY2025 GAAP operating loss −$35.3M on $32.5M revenue; Q1-2026 clean operating loss ≈ −$18.1M ex one-time items; gross margin compressed to 21.0% in Q1-2026 from 40.7% (mix shift to lower-margin government development service contracts).

Is net income diverging from cash from operations? Fact — and this is where entity hygiene matters. The FY2025 10-K’s “net loss” of −$66.9M is not Infleqtion operations: it is the SPAC shell’s non-cash −$69.6M mark-to-market loss on the PIPE subscription-agreement liability (CCX traded above $10 pre-close; extinguished at closing), plus $6.0M subscription expense and $2.0M G&A, offset by $10.7M trust interest. Post-close, the successor P&L is relatively clean versus typical de-SPACs: warrants and the founder earn-out are equity-classified, so no recurring fair-value remeasurement noise. Q1-2026’s −$30.3M net loss vs −$19.2M OCF is mostly one-time de-SPAC transaction costs ($11.5M) and SBC ($8.3M); clean operating burn ≈ −$8.5M–8.8M/qtr. Neither headline figure reflects the true ~$35M/yr underlying burn — which is what matters against $568.7M of liquidity (5+ years runway) and the ~$2.18B market cap (~$1.6–1.74B EV; ~52x EV/TTM sales; net cash ~$2.01/share).

Risks & Downside

What factors would cause the stock to decline? Fact/Interpretation. (i) Continued supply: five 424B3 resale filings in 14 weeks, formal 180-day lockup expiry ~2026-08-12, VC shares distributed to LPs still working through, short interest 13% of float and rising. (ii) Guidance risk: Q1 annualizes to ~$38M against the “at least $40M” guide — an H2-weighted, award-timing-dependent year on a $19.5M RPO base. (iii) LOI non-conversion: the ~$100M Commerce CHIPS award is a letter of intent, not contracted revenue. (iv) Sector-sentiment normalization (beta ~4.4; the May-June spike was entirely government-news-driven and has fully round-tripped). (v) Narrative damage from the DARPA QBI Stage-B exclusion while both neutral-atom rivals advanced. (vi) Dilution at bad prices if the R&D ramp forces a raise before sentiment recovers. (vii) A logical-qubit roadmap miss (30 targeted 2026).

Risk of a catastrophic loss? Interpretation — low near-term, real long-term. The catastrophic paths are technological (neutral-atom fails to scale / a rival modality wins, stranding the compute option) and financial (a quantum funding winter closing the equity window while burn ramps). But the near-term existential risk is capped by the balance sheet: $568.7M liquidity, no debt, ~5+ years of runway at current clean burn, price ~10x the NYSE $1 minimum. The realistic bear case is not zero — it is a quantum winter stalling revenue at $35–40M and compressing the multiple toward ~10x sales: EV ~$0.35–0.40B + cash ≈ ~$3.7/share, roughly −60% from $9.98, before any dilutive raise. Insiders selling and VC funds exiting at $14–18 rather than holding for the compute prize is its own datum on this question.

Chance of a total loss? Low on a 1–3 year view (cash floor ~$2.01/share, no debt, government revenue floor); non-trivial on a 5–10 year view if the technology and the funding window both fail — the equity is ultimately an option on an unproven modality, financed by a cash pile that depletes ~$35M+/yr.

Recent News & Events

Has the business environment changed recently? Fact. Yes — the 2026 U.S. policy stack is the demand driver: (1) Commerce Dept/NIST CHIPS R&D LOIs to nine quantum companies totaling $2.013B including government equity stakes (2026-05-21); Infleqtion’s allocation is ~$100M for large-scale systems engineering — non-dilutive validation but an LOI, milestone-gated, not booked revenue. (2) A U.S. Executive Order on quantum technology (2026-06-22); company responded with “America’s Quantum Space Initiative.” (3) Three DOE Genesis Mission projects awarded (2026-07-22: Argonne, Brookhaven, LLNL/CU Boulder). (4) UK announced up to GBP 2B of quantum investment (March 2026), citing Infleqtion’s NQCC delivery. The countervailing event: DARPA’s QBI Stage B (Nov 2025) advanced 11 companies including both neutral-atom rivals and excluded Infleqtion (it holds the HARC software-track win instead) — the closest thing to an official USG handicap of utility-scale credibility.

Significant acquisitions? None in-window; see the Capital Allocation section for the historical record (Super.tech 2022; Morton 2024, impaired).

Change in accounting policies? Auditor transition aligned to the merger: Withum (SPAC auditor) dismissed 2026-03-26; KPMG — Legacy Infleqtion’s auditor since 2022 — engaged for FY2026. Four ICFR material weaknesses disclosed; remediation may extend into 2027. Purchase-accounting noise is absent (reverse recapitalization).

Recent changes — new markets, facilities, management? New facilities/centers: Colorado, Oxford (UK Innovation Centre + manufacturing hub, opened 2026-05-28), and Chicago (Illinois IQMP/NQAC ~$50M partnership; fault-tolerant Sqale deployment announced 2026-07-22). New channels: Safran co-launched a Tiqker-based commercial timing product (April 2026). Management: Dr. Joseph Buck (ex-Lockheed Martin senior fellow, Caltech neutral-atom PhD) joined as SVP Quantum Computing Systems leading Sqale (2026-07-27/28) — the notable in-window hire; Nicholas Johnson (Churchill sponsor designee) appointed Class III director (2026-05-08); CEO Kinsella testified before the House Natural Resources Committee (2026-07-20). Q2-2026 earnings set for 2026-08-12 — the same day the formal lockup window expires.

Sources and labeling conventions are documented in Appendix B. All answers rest on public sources: SEC filings, earnings-call transcripts, and press.

APPENDIX B — Source Appendix

Infleqtion, Inc. (NYSE: INFQ) · Report date 2026-07-30

Primary sources first. All SEC filings are for CIK 0002007825 (Infleqtion, Inc., f/k/a Churchill Capital Corp X; Legacy operating company: ColdQuanta, Inc. d/b/a Infleqtion). Figures are reconciled to the filings. Third-party aggregators (AZI, FactorsToday, yfinance, MarketBeat) were used for cross-checks and are labeled as such. All web sources accessed 2026-07-30.

Reporting-basis map (load-bearing): the FY2025 Form 10-K contains the SPAC shell’s (CCX) financials only; Legacy Infleqtion’s audited FY2025/FY2024 statements are in the 8-K/A (2026-03-31, KPMG); FY2023/FY2024 + 9M-2025 are in the S-4/A; Q1-2026 onward is the successor company on a reverse-recapitalization basis. The FY2025 10-K net loss (−$66.9M) is the shell’s non-cash PIPE subscription mark, not Infleqtion operations.

Primary — SEC filings (EDGAR, CIK 0002007825)

Primary — Company communications

Secondary — Quantitative aggregators (cross-checks; reconcile to filings)

Secondary — Peer / industry cross-read

External reference (public)

Note on labeling: Facts are tied to primary filings/transcripts wherever possible. Interpretations (moat verdict, capital-cycle read, embedded-expectations math, scenario frame) are the analyst’s, labeled as such. Third-party aggregator figures (AZI, FactorsToday, yfinance, MarketBeat) are signals cross-checked against filings; where a discrepancy exists (e.g., FactorsToday’s stale ~193M share count, yfinance’s EV, pre-2026-02-17 CCCX price rows mapped onto INFQ), the filing governs.

Coverage note: fundamentals and transcripts were sourced from SEC EDGAR and public transcript providers. A third-party aggregator news sweep for 2026-07-15 → 07-31 surfaced no material item not already captured in the body (the DOE Genesis Mission awards, the IQMP Illinois deployment, the CEO’s House Natural Resources testimony, the Buck SVP appointment, and the 2026-08-12 Q2 date are all covered). If Drive context is later mounted, a re-read against transcript-derived claims (esp. the $300M+ pipeline and the never-restated “$50M booked and awarded” figure) is warranted.